Generex Biotechnology Corporation
(Public, NASDAQ:GNBT)
Anna Gluskin, CEO of Generex Biotechnology (NASDAQ:GNBT), talks about the company’s oral treatment for diabetes along with a cancer vaccine under development. MarketWatch’s Kristen Gerencher reports from the J.P. Morgan health-care conference in San Francisco.
Highlights
- Oral-Lyn is a liquid spray which allows the patients to be treated without injections (patient friendly)
- Not inhaled version, this product is absorbed by the cheeks, thus not entering the lungs
- It is given before meals, type 1 diabetes would only require one injection versus three or four
- 21 million patients with diabetes, Generex hopes to reach 10% of the market
Oral-Lyn Product
Generex Oral-lyn™, is an insulin spray for the treatment of Type I and Type II diabetes. Generex Oral-lyn™ is a safe, simple, fast, effective, and pain-free alternative to subcutaneous injections of prandial insulin and is conveniently delivered to the membranes of the oral cavity by a simple asthma-like device with no pulmonary (lung) deposition. As a pain-free and convenient method of insulin delivery, Generex Oral-lyn™ will allow individual patients to “fine tune” and then maintain their metabolism resulting in an improved quality of life. Accordingly, Generex Oral-lyn™ provides the opportunity for the establishment of a new and more efective diabetes treatment paradigm.
Generex Partnerships
Generex is dedicated to the research, development and commercialization of drugs delivery via the buccal mucosa. Generex seeks to out-license its RapidMist™ product programs and identify in-licensing opportunities and acquisitions in the areas of diabetes, drug delivery, cancer, H5 avian influenza, HIV, generic and branded prescription drugs, 505(b)2 product candidates, and late stage development opportunities.
Here are some of the companies we have partnered with; Please click on company urls the get the details.
Fertin Pharma
Fertin Pharma (www.fertin.com), is a world leader in the development and manufacture of medical chewing gum and is working in partnerships with a wide range of well-respected pharmaceutical companies. Fertin Pharma’s patent protected MediChew® technology is based on unique know-how with controlled release of active substances from gum bases, fully documented release testing procedures, taste modification, and development of gum bases.
Cardinal Health
Ranked No. 19 on the Fortune 500, Cardinal Health (www.cardinal.com), manufactures or packages products for nine out of the top 10 pharmaceutical companies and most leading biotechnology companies. The company manufactures or packages more than half a billion doses of pharmaceuticals every day.
Leosons General Trading Company
Leosons (www.leosons.com), a leading distributor of North American healthcare products in the region and the Company’s Marketing and Distribution partner in the Middle East, recently entered into a collaboration with Sheikh Saeed Bin Obaid Al Maktoum, a member of the Royal Family of United Arab Emirates. Recently, the two parties have established Medpro LLC with offices to be set up in the Dubai Healthcare City. Medpro is expected to market the Company’s products.
Adcock Ingram
Adcock Ingram (www.adcock.co.za), part of the Tiger Brands Group, is a leading South African pharmaceutical company with an 11.4% share of the private healthcare market. Adcock Ingram has an extensive range of prescription, generic, and over-the-counter products and also provides life saving hospital equipment and diagnostic products and services.
PharmaBrand SA
Ecuador-based Pharmabrand (www.pharmabrand.com), a distributor of pharmaceutical products, was established in June, 2000 with the acquisition of an Ecuadorian pharmaceuticals plant from Schering-Plough Corporation. Its management team, led by Dr. Cid, has extensive experience in the pharmaceutical industry. Dr. Cid holds a Doctoral Degree in Pharmacy and Chemistry from the University of Chile and a Master of Business Administration degree from Columbia University in New York. He has also undertaken graduate studies in strategic management at Harvard Business School. Dr. Cid has more than 30 years’ experience in the multinational pharmaceuticals industry, having held executive positions with Schering Plough, Pfizer and Merck. He served as General Manager & Regional Director of Latin America for Pfizer.
Shreya Life Sciences Pvt
Shreya Life Sciences Pvt. Ltd. (www.shreya.co.in), a leading Indian-based pharmaceutical company. Shreya is the fourth largest distributor of insulin in the Indian insulin product market with a compound annual growth rate of 38% (per C MARC market research). Shreya has interests in both pharmaceutical and biopharmaceutical products in key therapeutic segments including cardiology, neuropathy, and diabetes. The company has business operations in India, Russia, the Commonwealth of Independent States, and African countries. The parties are making arrangements for the expansion of extant production facilities to meet the anticipated demand for the product in India and other jurisdictions where governmental approvals are pending.
Benta Pharma Industries
Benta Pharma Industries (www.bpi.com.lb) is a state of the art manufacturing facility dedicated to the development of new and enhanced formulations of pharmaceutical products and production of a wide range of medical devices that fulfill most physicians’ needs. Benta production facility is designed in manner that constrains human direct interaction with the drug eliminating risks of contamination and cross contamination. Benta cooperate closely with its sister company Benta Trading for distribution and marketing of its products. Benta trading founded in 1968 is well known distribution company entrusted by many multinational companies for its high degree of flexibility creativity and expertise in this field. The management and personnel of BPI has been chosen with gigantic care to develop set of services.
About Generex Biotechnology Corporation
Generex Biotechnology Corporation (NasdaqCM: GNBT) is a leader in drug delivery for metabolic diseases through the inner lining of the mouth. Generex has developed a proprietary platform technology for the delivery of drugs into the human body through the oral cavity (with no deposit in the lungs). The Company’s proprietary liquid formulations allow drugs typically administered by injection to be absorbed into the body by the lining of the inner mouth.
Generex’s flagship product, Generex Oral-lyn™, an oral insulin spray for the treatment of diabetes, is approved for sale in India, Algeria, Lebanon and Ecuador, and is in Phase III clinical trials with over 347 patients being enrolled in 74 clinical sites around the world, including sites in the United States, Canada, Bulgaria, Poland, Romania, Russia and Ukraine. Also, Generex has developed MetControl™, a proprietary Metformin medicinal chewing gum, which is currently being prepared for submission to various regulatory authorities throughout the world.
Generex’s product pipeline includes: Generex Oral-lyn™, MetControl™ Metformin Gum, Glucose RapidSpray™, BaBOOM!™ Energy Spray, Crave-NX™ Day Diet Aid Spray, Fentanyl Spray, Morphine Spray, Breast and Prostate Cancer Vaccine and Avian Influenza Vaccine.
Generex’s wholly owned subsidiary, Antigen Express, Inc., concentrates on developing proprietary vaccine formulations that work by stimulating the immune system to either attack offending agents (i.e., cancer cells, bacteria, and viruses) or to stop attacking benign elements (i.e., self proteins and allergens). Clinical development of Antigen’s synthetic peptide vaccines designed to stimulate a potent and specific immune response against tumors expressing the HER-2/neu oncogene for patients with HER-2/neu positive breast cancer in a Phase II clinical trial and patients with prostate cancer and against avian influenza in two Phase I trials. Additional development efforts includes seasonal influenza virus, H5N1, HIV, HPV, melanoma, ovarian cancer, allergy and Type I diabetes mellitus.
Disclosure: Long GNBT
